Tuesday, March 15, 2011 10:22:45 AM
In a note to clients, J.P. Morgan writes, "With positive data in both advanced and naïve Parkinson's patients and 066 licensed to GSK outside of the US, Impax's investment in its branded business is beginning to show a return. We now see IPX 066 as a derisked asset that could have the potential to bring in more than $150 million in annual revenue with little further R&D outlay."
Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/03/926828/j-p-morgan-maintains-overweight-on-impax-laboratories-ipx#ixzz1Gg6YisWk
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM